Expanded scale Project Farma is a global leader in end-to-end pharmaceutical and biotech manufacturing with a track record of 100+ facility builds, 400+ large scale capital projects, and $6B+ in technical operations investments, indicating significant upsell opportunities in capital projects, facility modernization, and complex biologics manufacturing expansion for existing and new clients.

Strategic partnerships Recent acquisitions and collaborations with SimoTechnology, Oracle Primavera Cloud, and Valkit.ai signal a strategic push into GMP automation, advanced digital manufacturing, and AI-enabled validation, presenting cross-sell and product integration opportunities with customers seeking modernized, validated digital workflows.

Capital project demand With a revenue range of $100M-$250M and extensive experience managing large scale capital programs, there is a clear market signal for ongoing capital project management, PMIS optimization, and digital project collaboration tools among pharma manufacturers planning capacity expansions.

Biologics focus Expertise in complex biologics and novel modalities, along with end-to-end manufacturing lifecycle services, positions Project Farma to upsell advanced process development, facility readiness, and commercial manufacturing services to biotech firms and universities pursuing cutting-edge therapies.

Industry engagement Active participation and sponsorship at ISPE, Interphex, American Biomanufacturing Summit, and PDA events imply strong industry relationships; leveraging these connections can accelerate introductions to potential clients seeking validated manufacturing partners with a history of collaboration and patient-focused outcomes.